CELC launches REVTORPYK for HR-positive, HER2-negative advanced breast cancer
Celcuity (CELC) says REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and market-access groundwork. Phase III studies are ongoing, and expanded manufacturing is planned.
REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and robust market access groundwork. Based on Celcuity In…